Disclosed is the use of a composition comprising nanoparticles comprising paclitaxel and an albumin in the manufacture of a medicament for treatment of non-small cell lung cancer (NSCLC) in an individual, wherein the medicament is to be administered with an effective amount of a platinum-based agent such as carboplatin, wherein treatment is based upon the NSCLC having one or more characteristic selected from the group consisting of (i) differential levels of caveolin-1 (CAV1), (ii) differential levels of secreted protein acidic and rich in cysteine (SPARC), (iii) differential levels of hypoxia markers, (iv) differential levels of tumor acidity, (v) differential levels of gp60, (vi) differential levels of thymidylate synthase (TS), (vii) differential levels of S phase kinase-associated protein (Skp2), (viii) differential loss of heterozygosity (LOH) of single-nucleotide polymorphism (SNP), (ix) differential Kras mutations, (x) differential methylation of promoter region of tumor-related genes, and (xi) differential albumin uptake, wherein the treatment is based on the individual being at least about 70 years old.
